Aswanth Reddy

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Role not yet determined Is this you? Add your title

Arkansas Colleges of Health Education primary UA Fort Smith

Also affiliated: Mercy Medical Center (2024–2026); Vignan's Foundation for Science, Technology & Research (2025); John Peter Smith Hospital (2025); Cooper Green Mercy Hospital (2024–2026); Mercy Clinic Neurology (2023–2025); Mercy Hospital (2025); Unity Health System (2023); CHI Health Mercy Council Bluffs (2024–2026); Smith Clinic (2023–2026); Mercy Hospital (2024–2026); Rogers (United States) (2023–2025)

3 h-index 36 pubs 52 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Aswanth Reddy's research has focused on various aspects of cancer, particularly lung cancer, and its treatment. His work includes reviews of bispecific antibodies and antibody drug conjugates in immunotherapy, as well as investigating the role of specific mutations in non-small cell lung cancer response to pembrolizumab. Reddy has also explored cardiovascular events associated with anti-androgen therapy and documented a case of enzalutamide-induced non-ischemic cardiomyopathy. His research interests extend to the performance of multi-cancer detection tests. He has collaborated with researchers at the University of Arkansas – Fort Smith on numerous publications. Reddy's scholarship metrics include an h-index of 3, 36 total publications, and 52 total citations.

Metrics

h-index: 3
Publications: 36
Citations: 52

Selected Publications

POSTER: AML-708: Frailty as a Predictor of Chemotherapy Tolerance and Survival Outcomes in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
AML-708: Frailty as a Predictor of Chemotherapy Tolerance and Survival Outcomes in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
MDS-595: Atypical Immune-Mediated Pure Red Cell Aplasia: A Diagnostic Challenge (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Abstract PS5-04-16: Analysis of Efficacy, Safety and Cost of Datopotamab Deruxtecan and Sacituzumab Govitecan for Advanced Hormone Positive Breast Cancer Patients (2026)

Clinical Cancer Research DOI OpenAlex
Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102) (2026)

JNCI Journal of the National Cancer Institute 5 citations DOI OpenAlex
Mortality trends of chronic lymphocytic leukemia and pneumonia in the United States (1999–2023): A CDC-wonder analysis (2025)

Blood DOI OpenAlex
Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status (2025)

Blood DOI OpenAlex
Rising mortality trends in elderly multiple myeloma patients with hypertension: A CDC wonder database analysis (1999–2023) (2025)

Blood DOI OpenAlex
Comparative efficacy of complement inhibitors in complement Inhibitor–Naïve PNH: A network meta-analysis of randomized trials (2025)

Blood DOI OpenAlex
AML-463: Unraveling a Unique Presentation of Cold Agglutinin Disease in Myeloid Malignancy (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
A Rare Finding of Secondary Spontanous Pneumothorax (SSP) During Tyrosine Kinase Inhibitor Treatment of a Patient With Metastatic Synovial Sarcoma (2025)

American Journal of Respiratory and Critical Care Medicine 1 citation DOI OpenAlex
Treatment of Aggressive B Cell Lymphoma with Epcoritamab - Real World Single Institution Experience (2024)

Blood DOI OpenAlex
EP.11A.22 Comparing Outcomes and Adverse Events in Lung Cancer Immunotherapy: The Impact of Smoking Status (2024)

Journal of Thoracic Oncology 1 citation DOI OpenAlex
MM-361 Central Nervous System Relapse of Multiple Myeloma: A Case Report (2024)

Clinical Lymphoma Myeloma & Leukemia 1 citation DOI OpenAlex